Bivalirudin Use With Percutaneous Ventricular Assist Device in Suspected Heparin-Induced Thrombocytopenia

Abstract

Get full access to this article

View all access options for this article.

References

Abiomed Inc. 5% Dextrose with heparin as default Impella purge solution. https://www.abiomedtraining.com/pdf/14864898121bf5cc54722a9e59410f33c96eadb10a.pdf;https://www.abiomed.us/assets/HCS-TB01029-rA_Dextrose_with_Heparin_as_Default_Impella_Purge_Solution.pdf. Accessed May 13, 2019.

Weeks

Sieg

Rajapreyar

et al. Bivalirudin for left ventricular assist device thrombosis. Bivalirudin for left ventricular assist device thrombosis. J Thromb Thrombolysis. 2018;46:496-501. doi:10.1007/s11239-018-1725-z

Blum

Martz

Selektor

Nemeh

Smith

Anticoagulation of percutaneous ventricular assist device using argatroban-based purge solution: a case series. J Pharm Pract. 2018;31:514-518. doi:10.1177/0897190017727191

Laliberte

Reed

BN.

Use of an argatroban-based purge solution in a percutaneous ventricular assist device. Am J Health Syst Pharm. 2017;74:e163-e169. doi:10.2146/ajhp160212

Reed

DiDomenico

Allender

, et al. Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers. J Interv Cardiol. 2019;2019:3791307. doi:10.1155/2019/3791307